Piccolella Margherita, Crippa Valeria, Cristofani Riccardo, Rusmini Paola, Galbiati Mariarita, Cicardi Maria Elena, Meroni Marco, Ferri Nicola, Morelli Federica F, Carra Serena, Messi Elio, Poletti Angelo
Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Milano, Italy.
C. Mondino National Neurological Institute, Pavia, Italy.
Oncotarget. 2017 Feb 7;8(6):10400-10415. doi: 10.18632/oncotarget.14422.
Breast cancer (BC) is one of the major causes of cancer death in women and is closely related to hormonal dysregulation. Estrogen receptor (ER)-positive BCs are generally treated with anti hormone therapy using antiestrogens or aromatase inhibitors. However, BC cells may become resistant to endocrine therapy, a process facilitated by autophagy, which may either promote or suppress tumor expansion. The autophagy facilitator HSPB8 has been found overexpressed in some BC. Here we found that HSPB8 is highly expressed and differentially modulated by natural or synthetic selective ER modulators (SERMs), in the triple-positive hormone-sensitive BC (MCF-7) cells, but not in triple-negative MDA-MB-231 BC cells. Specific SERMs induced MCF-7 cells proliferation in a HSPB8 dependent manner whereas, did not modify MDA-MB-231 cell growth. ER expression was unaffected in HSPB8-depleted MCF-7 cells. HSPB8 over-expression did not alter the distribution of MCF-7 cells in the various phases of the cell cycle. Conversely and intriguingly, HSPB8 downregulation resulted in an increased number of cells resting in the G0/G1 phase, thus possibly reducing the ability of the cells to pass through the restriction point. In addition, HSPB8 downregulation reduced the migratory ability of MCF-7 cells. None of these modifications were observed, when another small HSP (HSPB1), also expressed in MCF-7 cells, was downregulated. In conclusion, our data suggest that HSPB8 is involved in the mechanisms that regulate cell cycle and cell migration in MCF-7 cells.
乳腺癌(BC)是女性癌症死亡的主要原因之一,且与激素失调密切相关。雌激素受体(ER)阳性的乳腺癌通常采用抗雌激素或芳香化酶抑制剂进行抗激素治疗。然而,乳腺癌细胞可能会对内分泌治疗产生耐药性,自噬促进了这一过程,自噬可能促进或抑制肿瘤扩张。已发现自噬促进因子HSPB8在某些乳腺癌中过表达。在此我们发现,在三阳性激素敏感型乳腺癌(MCF-7)细胞中,HSPB8高度表达且受天然或合成选择性雌激素受体调节剂(SERM)的差异调节,但在三阴性MDA-MB-231乳腺癌细胞中则不然。特定的SERM以HSPB8依赖的方式诱导MCF-7细胞增殖,而对MDA-MB-231细胞的生长没有影响。在HSPB8缺失的MCF-7细胞中,ER表达不受影响。HSPB8的过表达并未改变MCF-7细胞在细胞周期各阶段的分布。相反且有趣的是,HSPB8的下调导致处于G0/G1期的细胞数量增加,从而可能降低细胞通过限制点的能力。此外,HSPB8的下调降低了MCF-7细胞的迁移能力。当同样在MCF-7细胞中表达的另一种小热休克蛋白(HSPB1)下调时,未观察到这些变化。总之,我们的数据表明,HSPB8参与了调节MCF-7细胞周期和细胞迁移的机制。